Vericel

Vericel Corporation
Vericel Corporation
Formerly	Aastrom Biosciences, Inc.
Type	Public
Traded as	Nasdaq: VCEL; Russell 2000 component; S&P 600 component
Industry	Biotechnology
Founded	1989; 37 years ago in Ann Arbor, Michigan, United States
Headquarters	Cambridge, Massachusetts, United States
Number of locations	2
Key people	Nick Colangelo (CEO); Daniel Orlando (COO); Gerard Michel (CFO);
Products	MACI; Epicel; Carticel;

Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.

In the spring of 2014, Aastrom Bio acquired Sanofi's cell therapy and regenerative medicine business which Sanofi had acquired when purchasing Genzyme in 2011. This transformed Aastrom in several ways: it increased the employee count by 8-fold and provided a revenue stream and products to market, which it had not had before.

In October 2014, the company changed its name from Aastrom Bio to Vericel and relocated its headquarters from Ann Arbor, Michigan to Cambridge, Massachusetts.

References

1 2 3 4 Seiffert, Don (21 Oct 2014). "In Vericel, an old Genzyme business gets new life and space in Cambridge". bioflash. Boston Bus. J.

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by adding missing information.

[seiffert2014-1] 1 2 3 4 Seiffert, Don (21 Oct 2014). "In Vericel, an old Genzyme business gets new life and space in Cambridge". bioflash. Boston Bus. J.